SK Biopharm’s Epilepsy Drug ‘Xcopri’ Wins Korean Approval
SK Biopharm’s Epilepsy Drug ‘Xcopri,’ with ₩400 Billion ($290 Million) Annual U.S. Sales, Wins Korean Approval SK Biopharm’s…
SK Biopharm
4 개의 기사가 있습니다.
SK Biopharm Targets KRW 700 Billion in Annual Sales on Strong Epilepsy Drug Growth
SK Biopharm has set its sights on surpassing KRW 700 billion (approximately $515 million) in annual sales this…
SK Biopharm Strengthens R&D with Former GSK Experts at U.S. Subsidiary
SK Biopharm is strengthening its research and development capabilities by securing top-tier talent. The company announced on the…
"SK Biopharm's Epilepsy Drug Excels in the U.S."... Growth Expected in the Second Half
SK Biopharm is expected to continue its performance growth in the second half of the year, driven by…